COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00097734
Recruitment Status : Unknown
Verified February 2006 by Klinikum Hanover-Siloah Hospital.
Recruitment status was:  Recruiting
First Posted : November 30, 2004
Last Update Posted : February 14, 2006
Information provided by:
Klinikum Hanover-Siloah Hospital

Brief Summary:
The purpose of this study is to compare the efficacy (by assessing the clinical success of treatment) of intravenous antibiotic therapy with ertapenem in patients with acute attacks of sigmoid diverticulitis for 4 vs. 7 days.

Condition or disease Intervention/treatment Phase
Diverticulitis, Colonic Acute Disease Drug: ertapenem Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 540 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Educational/Counseling/Training
Official Title: A Prospective, Multicenter, Open-Label, Randomized Clinical Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis
Study Start Date : July 2004
Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Clinical therapeutic success (full regression)
  2. Relapse rate
  3. Operation rate

Secondary Outcome Measures :
  1. Development of laboratory parameters
  2. Duration of hospitalization
  3. Duration of parenteral feeding
  4. Incidence of surgical intervention and repeat surgery
  5. Incidence and duration of intensive care

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least three of the following signs or symptoms of an acute attack of sigmoid diverticulitis must be present: *Fever (body temperature > 38°C, sublingual), *Abdominal tenderness, *Leukocytosis (leukocytes > 10,000/µl) and left shift of the differential blood count (>1% band forms), *Elevated CRP (> 20 mg/l)
  • Evidence of sigmoid diverticulitis by contrast enema
  • CT evidence of wall thickening in the sigmoid intestine
  • Decision in favor of conservative therapy on the basis of the case history and diagnosis

Exclusion Criteria:

  • Contraindication for the use of the study medication or other beta-lactam antibiotics, e.g. patients with advanced renal impairment or patients requiring hemodialysis
  • Antibiotic therapy in the two weeks prior to the start of the study
  • Patients with an advanced incurable disease
  • Patients with a hematologic/oncologic disease (leukemia, lymphoma)
  • Patients on immunosuppressants
  • Complications of sigmoid diverticulitis leading to an immediate indication for surgery
  • Patients who have hypersensitivity to beta-lactam antibiotics
  • Female patients who are pregnant or nursing or who could become pregnant during the study
  • Participation in another clinical study or use of another study drug within the four weeks prior to enrollment in the study or use of another drug during the study
  • Each patient can be enrolled only once in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00097734

Layout table for location contacts
Contact: Ferdinand Koeckerling, Prof. Dr. 0049-511-927-2331
Contact: Omar Huegel, Dr. 0049-511-927-2331

Layout table for location information
Klinikum Hannover- Krankenhaus Siloah Recruiting
Hannover, Germany, 30449
Contact: Omar Huegel, Dr.    0049-511-927-2331      
Principal Investigator: Ferdinand Koeckerling, Prof. Dr.         
Sub-Investigator: Omar Huegel, Dr.         
Sub-Investigator: Pascal Geers, Dr.         
Sponsors and Collaborators
Klinikum Hanover-Siloah Hospital
Layout table for investigator information
Study Chair: Ferdinand Koeckerling, Prof. Dr. Klinikum Hanover-Siloah hospital and Nordstadt hospital- Surgical Department

Layout table for additonal information Identifier: NCT00097734    
Other Study ID Numbers: mc317
First Posted: November 30, 2004    Key Record Dates
Last Update Posted: February 14, 2006
Last Verified: February 2006
Keywords provided by Klinikum Hanover-Siloah Hospital:
acute attacks
sigmoid diverticulitis
Acute attacks of sigmoid diverticulitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Diverticulitis, Colonic
Acute Disease
Diverticular Diseases
Intraabdominal Infections
Gastrointestinal Diseases
Digestive System Diseases
Disease Attributes
Pathologic Processes
Diverticulosis, Colonic
Colonic Diseases
Intestinal Diseases
Anti-Bacterial Agents
Anti-Infective Agents